Showing 7731-7740 of 10548 results for "".
- Alumis Closes $259 Million Financing to Help Launch Phase 3 Psoriasis Trial for Lead Asset ESK-001https://practicaldermatology.com/news/alumis-closes-259-million-financing-to-help-launch-phase-3-psoriasis-trial-for-lead-asset/2462267/In this year's largest privite biotech fundraise to date, Alumis announced $259 million Series C financing to initiate pivotal phase 3 clinical trials for its lead candidate ESK-001, a highly selective allosteric tyrosine kinase 2 (TYK2) inhibitor, in moderate to severe pl
- Cyndi Lauper to Host New Novartis PsO Podcasthttps://practicaldermatology.com/news/cyndi-lauper-to-host-new-novartis-pso-podcast/2460514/Novartis is launching PsO in the Know, a podcast series hosted by music icon Cyndi Lauper. PsO in the Know will feature a variety of guests, including Chef Aarón Sánchez, actress and New York Times best-selling author La La Anthony, and Emmy
- Botox Hits the Big 3-0https://practicaldermatology.com/news/botox-hits-the-big-3-0/2460184/Botox is turning 30, and Allergan fêted its shining star, Botox Cosmetic, in style at a New York City bash. The event included the debut of Botox Cosmetic’s new packaging and a panel discussion featuring New York City dermatologists Macrene Alexiades-Armenakas, MD, PhD
- L'Oréal Debuts Wearable Electronic UV Monitorhttps://practicaldermatology.com/news/loral-debuts-wearable-electronic-uv-monitor/2458740/Earlier this month at the Consumer Electronics Show, L’Oréal unveiled My UV Patch, a stretchable skin sensor designed to monitor UV exposure and help consumers educate themselves about sun protection. L’Oréal Group’s dermatological skincare brand, La Roche-Posay, i
- Letter Questions Strength of Evidence Linking Hair Relaxers to Uterine Cancerhttps://practicaldermatology.com/news/letter-questions-strength-of-evidence-linking-hair-relaxers-to-uterine-cancer/2487618/A recently published Letter to the Editor in the Journal of Drugs in Dermatology urged clinicians to interpret the growing body of research examining chemical hair relaxers and uterine cancer with caution, arguing that important methodological limitations prevent current evidence from es
- Low Infection Risk Across Psoriasis Biologics Reported in Real-World Studyhttps://practicaldermatology.com/news/low-infection-risk-across-psoriasis-biologics-reported-in-real-world-study/2487541/A large real-world analysis published in the Journal of the American Academy of Dermatology indicates biologic therapies for psoriasis are associated with low overall infection risk, with ustekinumab and interleukin (IL)-23
- FDA Approves OTC Switch for Galderma’s Differin Epiduo Acne Gelhttps://practicaldermatology.com/news/fda-approves-otc-switch-for-galdermas-differin-epiduo-acne-gel/2487203/The US Food and Drug Administration (FDA) has approved Galderma’s Differin Epiduo Acne Gel (adapalene 0.1% and benzoyl peroxide 2.5%) for over-the-counter (OTC) use in patients aged 12 years and older, marking a notable prescription-to-OTC transition in acne therap
- Topical NAC Plus Doxycycline Shows Benefit in Moderate Acnehttps://practicaldermatology.com/news/topical-nac-plus-doxycycline-shows-benefit-in-moderate-acne/2486948/Topical N-acetylcysteine (NAC) plus doxycycline was associated with greater improvement than benzoyl peroxide (BPO) plus doxycycline in patients
- Study: GLP-1 Linked with PASI Reductionshttps://practicaldermatology.com/news/early-evidence-links-glp-1-therapy-to-pasi-reductions/2486929/Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are gaining attention as a potential adjunctive therapy in psoriasis, according to a new review from the National Psoriasis Foundation Medical Board published in JAMA Dermatol
- TRuE-AD4: Ruxolitinib Cream Improves QoL and Sleep in Moderate ADhttps://practicaldermatology.com/news/true-ad4-ruxolitinib-cream-improves-qol-and-sleep-in-moderate-ad/2486434/Ruxolitinib cream 1.5% demonstrated consistent improvements in patient-reported outcomes among adults with moderate atopic dermatitis (AD) who previously had inadequate response, intolerance, or contraindications to topical corticosteroids (TCS) and topical calcine